#### **Supporting Online Material for**

## Total Syntheses of (+)-Epilupinine *via* An Intramolecular Nitrile Oxide-Alkene Cycloaddition

Deyong Su, Xinyan Wang,\* Changwei Shao, Jimin Xu, Rui Zhu, Yuefei Hu\*

Department of Chemistry, Tsinghua University, Beijing 100084, P. R. China

wangxinyan@mail.tsinghua.edu.cn, yfh@mail.tsinghua.edu.cn,

Page 03-21: Materials and Methods.

Page 22-83: the <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for compounds.

Page 22	<sup>1</sup> H NMR of ( <i>R</i> )-5·HCl	Page 23	<sup>13</sup> C NMR of ( <i>R</i> )-5·HCl
Page 24	<sup>1</sup> H NMR of <b>11a</b>	Page 25	<sup>13</sup> C NMR of <b>11a</b>
Page 26	<sup>1</sup> H NMR of <b>12a</b>	Page 27	<sup>13</sup> C NMR of <b>12a</b>
Page 28	<sup>1</sup> H NMR of <b>12b</b>	Page 29	<sup>13</sup> C NMR of <b>12b</b>
Page 30	<sup>1</sup> H NMR of <b>12c</b>	Page 31	<sup>13</sup> C NMR of <b>12c</b>
Page 32	<sup>1</sup> H NMR of <b>12d</b>	Page 33	<sup>13</sup> C NMR of <b>12d</b>
Page 34	<sup>1</sup> H NMR of <b>12e</b>	Page 35	<sup>13</sup> C NMR of <b>12e</b>
Page 36	<sup>1</sup> H NMR of <b>12f</b>	Page 37	<sup>13</sup> C NMR of <b>12f</b>
Page 38	<sup>1</sup> H NMR of <b>12g</b>	Page 39	<sup>13</sup> C NMR of <b>12g</b>
Page 40	<sup>1</sup> H NMR of <b>12h</b>	Page 41	<sup>13</sup> C NMR of <b>12h</b>
Page 42	<sup>1</sup> H NMR of <b>12i</b>	Page 43	<sup>13</sup> C NMR of <b>12i</b>
Page 44	<sup>1</sup> H NMR of <b>12j</b>	Page 45	<sup>13</sup> C NMR of <b>12j</b>
Page 46	<sup>1</sup> H NMR of <b>12k</b>	Page 47	<sup>13</sup> C NMR of <b>12k</b>
Page 48	<sup>1</sup> H NMR of <b>13a</b>	Page 49	<sup>13</sup> C NMR of <b>13a</b>
Page 50	<sup>1</sup> H NMR of <b>13b</b>	Page 51	<sup>13</sup> C NMR of <b>13b</b>
Page 52	<sup>1</sup> H NMR of <b>13c</b>	Page 53	<sup>13</sup> C NMR of <b>13c</b>
Page 54	<sup>1</sup> H NMR of <b>13d</b>	Page 55	<sup>13</sup> C NMR of <b>13d</b>
Page 56	<sup>1</sup> H NMR of <b>13e</b>	Page 57	<sup>13</sup> C NMR of <b>13e</b>
Page 58	<sup>1</sup> H NMR of <b>13f</b>	Page 59	<sup>13</sup> C NMR of <b>13f</b>
Page 60	<sup>1</sup> H NMR of <b>13g</b>	Page 61	<sup>13</sup> C NMR of <b>13g</b>
Page 62	<sup>1</sup> H NMR of <b>13h</b>	Page 63	<sup>13</sup> C NMR of <b>13h</b>
Page 64	<sup>1</sup> H NMR of <b>13i</b>	Page 65	<sup>13</sup> C NMR of <b>13i</b>
Page 66	<sup>1</sup> H NMR of <b>13j</b>	Page 67	<sup>13</sup> C NMR of <b>13j</b>
Page 68	<sup>1</sup> H NMR of <b>13k</b>	Page 69	<sup>13</sup> C NMR of <b>13k</b>
Page 70	<sup>1</sup> H NMR of <b>14a</b>	Page 71	<sup>13</sup> C NMR of <b>14a</b>
Page 72	<sup>1</sup> H NMR of <b>14b</b>	Page 73	<sup>13</sup> C NMR of <b>14b</b>
Page 74	<sup>1</sup> H NMR of <b>14c</b>	Page 75	<sup>13</sup> C NMR of <b>14c</b>
Page 76	<sup>1</sup> H NMR of <b>14d</b>	Page 77	<sup>13</sup> C NMR of <b>14d</b>
Page 78	<sup>1</sup> H NMR of <b>15</b>	Page 79	<sup>13</sup> C NMR of <b>15</b>
Page 80	<sup>1</sup> H NMR of <b>16</b>	Page 81	<sup>13</sup> C NMR of <b>16</b>
Page 82	<sup>1</sup> H NMR of (+)-Epilupinine (2)	Page 83 $^{13}$ C	NMR of (+)-Epilupinine (2)

### List of <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for compounds.

#### **Materials and Methods**

**General Method:** All melting points were determined on a Yanaco melting point apparatus and are uncorrected. IR spectra were recorded on a Nicolet FT-IR 5DX spectrometer. The <sup>1</sup>H NMR (300 MHz) and <sup>13</sup>C NMR (75 MHz) spectra were recorded on a JEOL JNM-ECA 300 spectrometer in CDCl<sub>3</sub> with TMS as internal reference. The *J* values are given in Hz. MS were recorded on a VG-ZAB-MS spectrometer with 70 eV. Elementary analysis data were obtained on a Perkin-Elmer-241C apparatus.

The starting material  $\mathbf{3}^{18}$  and the intermediate  $\mathbf{4}^{10b}$  were prepared by the reference methods.



**Preparation of** (*R*)**-2-vinylpiperidine Hydrochloride** [(*R*)**-5·HCl]:** To a cold solution (ice-water bath) of compound **4** (1.02 g, 3 mmol) in dry THF (20 mL) was added LiAlH<sub>4</sub> (170 mg, 4.5 mmol) under N<sub>2</sub>. After the reaction was stirred at 0 °C for 30 min (monitored by TLC), a saturated aqueous solution of NH<sub>4</sub>Cl (30 mL) was added to quench the reaction. Then the resultant mixture was extracted with Et<sub>2</sub>O (3 x 10 mL). The combined organic layers were washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>.

After removal of the solvent, the residue was diluted by a solution of THF (4 mL),  $CH_3OH$  (4 mL) and aq. NaOH (6.0 M, 2 mL). The resultant mixture was stirred at 60

°C for 6 h and then was cooled to room temperature. It was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 10 mL) and the combined organic layers were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After the solid was filtered off, the filtrate was immediately treated with saturated solution of HCl in MeOH (6 mL) at 0 °C for 30 min. Then, the solvent was removed in vacuum and the residue was recrystallized from MeOH-Et<sub>2</sub>O to give product (*R*)-5·HCl as a white crystal (410 mg, 93%). It had mp 199-200 °C (MeOH-Et<sub>2</sub>O).  $[\alpha]_D^{20} = +5.5$  (c 0.2, CHCl<sub>3</sub>); IR: *v* 3440, 2983, 1252, 1013 cm<sup>-1</sup>. <sup>1</sup>H NMR:  $\delta$ 9.53-9.40 (m, 2H), 6.13-6.02 (m, 1H), 5.56-5.37 (m, 2H), 3.60-3.43 (m, 2H), 2.95-2.88 (m, 1H), 2.04-1.82 (m, 5H), 1.55-1.52 (m, 1H); <sup>13</sup>C NMR:  $\delta$ 133.3, 120.5, 58.1, 44.2, 28.1, 21.8, 21.5; MS *m*/*z* (%): 111 (M<sup>+</sup>-HCl, 1.71), 84 (100). Anal. Calcd. For C<sub>7</sub>H<sub>14</sub>ClN: C, 56.94; H, 9.56; N, 9.49. Found: C, 56.67; H, 9.43; N, 9.66.



**Preparation of (***R***)-3-(2-vinylpiperidin-1-yl)propan-1-ol (11a):** The mixture of compound (*R*)-5-HCl (2.00 g, 13.5 mmol), ClCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH (1.42 g, 15 mmol), dry K<sub>2</sub>CO<sub>3</sub> (4.14 g, 30 mmol) and KI (2.49 g, 15 mmol) in acetone (50 mL) was refluxed for 2 h. Then the solid was filtrated off and the solvent was evaporated. The residue was purified by chromatography (silica gel, EtOAc) to give 2.18 g (95%) of product 11a as a colorless oil,  $[\alpha]_D^{20} = +76.4$  (c 0.2, CHCl<sub>3</sub>). IR: *v* 3387, 2933, 2857, 1053 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ5.78-5.67 (m, 1H), 5.49 (s, 1H), 5.10-4.99 (m, 2H), 3.70-3.63 (m, 2H), 3.10-2.87 (m, 2H), 2.53-2.48 (m, 1H), 2.23-2.14 (m, 1H), 1.86-1.25 (m, 9H); <sup>13</sup>C NMR:

*δ*141.0, 116.0, 66.9, 64.2, 54.9, 51.7, 33.5, 27.1, 25.5, 23.3; MS *m/z* (%): 169 (M<sup>+</sup>, 1.87), 124 (100). Anal. Calcd for C<sub>10</sub>H<sub>19</sub>NO: C, 70.96; H, 11.31; N, 8.28. Found: C, 71.21; H, 11.24; N, 8.32.



Preparation of *N*-[(2*R*)-2-vinyl-1-piperidine-propyl]-*N*-[(*tert*-butyldimethylsilyl)oxy]-4-methyl-benzenesulfonamide (12a), A typical procedure of Mutsunobu reaction: To a stirred solution of 11a (508 mg, 3 mmol), TsNHOTBS (915 mg, 3.15 mmol), PPh<sub>3</sub> (1.58 g, 6 mmol) and THF (3 mL) in toluene (9 mL) was added a solution of DEAD (784 mg, 4.5 mmol) in toluene (3 mL) at 0 °C under N<sub>2</sub>. One hour later, the solvent was removed to give a residue, which was purified by chromatography (silica gel, 10% EtOAc in PE) to give 1.33 g (98%) of product **12a** as a colorless oil,  $[\alpha]_D^{20}$ = +21.0 (c 0.2, CHCl<sub>3</sub>). IR: *v* 2932, 2856, 1465 cm<sup>-1</sup>; <sup>1</sup>H NMR: *δ*7.73 (d, *J* = 8.2, 2H), 7.33 (d, *J* = 7.9, 2H), 5.71-5.62 (m, 1H), 5.12-4.98 (m, 2H), 3.02-2.83 (m, 3H), 2.71-2.51 (m, 2H), 2.44 (s, 3H), 2.16-2.06 (m, 1H), 1.97-1.91 (m, 1H), 1.74-1.23 (m, 8H), 0.93 (s, 9H), 0.30 (s, 6H); <sup>13</sup>C NMR: *δ*144.3, 141.8, 129.9, 129.7 (2C), 129.1 (2C), 115.3, 66.4, 54.3, 52.4, 51.9, 33.5, 25.9 (3C), 25.8, 23.7, 23.5, 21.5, 18.0. -4,4 (2C); MS *m*/*z* (%): 452 (M<sup>+</sup>, 1.08), 44 (100). Anal. Calcd for C<sub>23</sub>H<sub>40</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 61.02; H, 8.91; N, 6.19. Found: C, 61.25; H, 8.99; N, 6.06. By similar procedure, 3-aminopropanols **11b-11k** were converted into the corresponding 4-methyl-benzenesulfonamides **12b-12k**.



*N*-[3-[*N*-Allyl-*N*-butylamino]propyl]-*N*-(*tert*-butyldimethylsilyloxy)-4-methylbenzenesulfonamide (12b): It is a yellowish oil (97%); IR: *v* 2956, 2931, 1359 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  7.73 (d, *J* = 7.9, 2H), 7.33 (d, *J* = 7.9, 2H), 5.86-5.74 (m, 1H), 5.15-5.06 (m, 2H), 3.07-2.92 (m, 4H), 2.45 (s, 3H), 2.40-2.32 (m, 4H), 1.73-1.63 (m, 2H), 1.45-1.19 (m, 5H), 0.92 (s, 9H), 0.90-0.86 (m, 2H), 0.30 (s, 6H); <sup>13</sup>C NMR:  $\delta$  144.4, 136.0, 129.9, 129.8 (2C), 129.2 (2C), 116.9, 57.1, 54.3, 53.4, 50.9, 29.1, 26.0 (3C), 24.7, 21.6, 20.5, 18.2, 14.0, -4.3 (2C); MS *m*/*z* (%): 454 (M<sup>+</sup>, 5.08), 84 (100). Anal. Calcd for C<sub>23</sub>H<sub>42</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 60.75; H, 9.31; N, 6.16. Found: C, 60.51; H, 9.18; N, 6.29.



N-[3-(N,N-Diallylamino)propyl]-N-(tert-butyldimethylsilyloxy)-4-methyl-

**benzenesulfonamide** (12c): It is a yellowish oil (96%); IR: *ν* 3074, 2955, 2929, 1471, 1358 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ7.73 (d, *J* = 7.9, 2H), 7.33 (d, *J* = 7.9, 2H), 5.86-5.74 (m, 2H), 5.16-5.08 (m, 4H), 3.03-3.01 (d, *J* = 6.2, 4H), 2.98-2.92 (t, *J* = 6.9, 2H), 2.44-2.38 (m, 5H), 1.74-1.67 (m, 2H), 0.93 (s, 9H), 0.30 (s, 6H); <sup>13</sup>C NMR: δ 144.3, 135.6 (2C), 130.0, 129.8 (2C), 129.1 (2C), 117.1 (2C), 56.7 (2C), 54.2, 50.4, 25.9 (3C), 24.7, 21.5, 18.1, -4.3 (2C). MS *m*/*z* (%): 438 (M<sup>+</sup>, 0.28), 110 (100). Anal. Calcd for C<sub>22</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 60.23; H, 8.73; N, 6.39. Found: C, 60.46; H, 8.67; N, 6.46.



N-[3-(N-Allyl-N-but-3-enyl)aminopropyl]-N-(tert-butyldimethylsilyloxy)-4-

methyl-benzenesulfonamide (12d): It is a yellowish oil (96%); IR: *v* 3075, 2928, 1598, 1465, 1359 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$ 7.73 (d, *J* = 8.3, 2H), 7.33 (d, *J* = 8.3, 2H), 5.83-5.70 (m, 2H), 5.16-4.94 (m, 4H), 3.04-3.02 (d, *J* = 6.2, 2H), 2.97-2.91 (m, 2H), 2.47-2.38 (m, 7H), 2.14-2.10 (m, 2H), 1.73-1.63 (m, 2H), 0.92 (s, 9H), 0.29 (s, 6H); <sup>13</sup>C NMR:  $\delta$  144.3, 136.6, 135.7, 129.9, 129.7 (2C), 129.1 (2C), 116.9, 115.3, 56.9, 54.2, 53.0, 50.7, 31.3, 25.9 (3C), 24.7, 21.5, 18.1, -4.3 (2C); MS *m/z* (%): 452 (M<sup>+</sup>, 0.24), 84 (100). Anal. Calcd for C<sub>23</sub>H<sub>40</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 61.02; H, 8.91; N, 6.19. Found: C, 61.19; H, 9.10; N, 6.06.



*N*-[**3**-(*N*-**But-3**-**enyl**-*N*-**butyl**)**aminopropyl**]-*N*-(*tert*-**butyldimethylsilyloxy**)-**4**-**m ethyl-benzenesulfonamide** (**12e**): It is a colorless oil (97%). IR: *v* 3073, 2955, 1598, 1462, 1357 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ7.73 (d, *J* = 8.3, 2H), 7.33 (d, *J* = 7.9, 2H), 5.80-5.71 (m, 1H), 5.04-4.94 (m, 2H), 2.96-2.91 (m, 2H), 2.45-2.32 (m, 9H), 2.16-2.08 (m, 2H), 1.70-1.60 (m, 2H), 1.37-1.22 (m, 4H), 0.92 (s, 9H), 0.91-0.81 (m, 3H), 0.30 (s, 6H); <sup>13</sup>C NMR:  $\delta$  144.3, 136.9, 129.9, 129.8 (2C), 129.1 (2C), 115.2, 54.4, 53.5, 53.3, 51.2, 31.4, 29.2, 25.9 (3C), 24.8, 21.5, 20.5, 18.1, 14.0, -4.3 (2C); MS *m*/*z* (%): 468 (M<sup>+</sup>, 1.42), 427 (100). Anal. Calcd for C<sub>24</sub>H<sub>44</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 61.49; H, 9.46; N, 5.98. Found: C, 61.57; H, 9.63; N, 5.88.



*N*-[**3**-(*N*-benzyl-*N*-but-**3**-enyl)aminopropyl]-*N*-(*tert*-butyldimethylsilyloxy)-**4**methyl-benzenesulfonamide (**12f**): It is a colorless oil (96%); IR: *v* 2959, 2931, 1457, 1358 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  7.71 (d, *J* = 7.9, 2H), 7.32-7.20 (m, 7H), 5.80-5.65 (m, 1H), 5.02-4.92 (m, 2H), 3.50 (s, 2H), 2.95-2.90 (m, 2H), 2.48-2.37 (m, 7H), 2.23-2.14 (m, 2H), 1.74-1.65 (m, 2H), 0.91 (s, 9H), 0.27 (s, 6H); <sup>13</sup>C NMR:  $\delta$  144.3, 139.6, 136.8, 129.84, 129.79 (2C), 129.1 (2C), 128.6 (2C), 128.0 (2C), 126.7, 115.4, 58.3, 54.3, 53.0, 50.9, 31.4, 26.0 (3C), 24.8, 21.6, 18.1, -4.3 (2C); MS *m*/*z* (%): 502 (M<sup>+</sup>, 1.10), 91 (100). Anal. Calcd for C<sub>27</sub>H<sub>42</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 64.50; H, 8.42; N, 5.57. Found: C, 64.55; H, 8.36; N, 5.61.



*N*-[**3**-[**3**,**4**-dihydroisoquinolin-2(1*H*)-yl]propyl]-*N*-(*tert*-butyldimethylsilyloxy)-**4-methyl-benzenesulfonamide (12g):** It is a colorless oil (99%); IR: *v* 3746, 2938,

1462, 1353 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$ 7.73 (d, *J* = 7.9, 2H), 7.29 (d, *J* = 7.9, 2H), 7.12-7.05 (m, 3H), 6.98-6.95 (m, 1H), 3.55 (s, 2H), 3.05-3.00 (m, 2H), 2.86-2.82 (m, 2H), 2.68-2.63 (m, 2H), 2.53-2.47 (m, 2H), 2.40 (s, 3H), 1.88-1.83 (m, 2H), 0.93 (s, 9H), 0.31 (s, 6H); <sup>13</sup>C NMR:  $\delta$ 144.3, 134.6, 134.1, 129.8, 129.7 (2C), 129.1 (2C), 128.4, 126.3, 125.9, 125.4, 55.9, 55.4, 54.2, 50.7, 28.9, 25.9 (3C), 24.7, 21.5, 18.0, -4.4 (2C); MS *m*/*z* (%): 474 (M<sup>+</sup>, 0.69), 146 (100). Anal. Calcd for C<sub>25</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 63.25; H, 8.07; N, 5.90. Found: C, 63.37; H, 8.12; N, 5.83.



*N*-[**3**-(**Piperidin-1-yl**)**propyl**]-*N*-(*tert*-butyldimethylsilyloxy)-4-methyl-benzene sulfonamide (12h): It is a colorless oil (96%); IR: *v* 2932, 2857, 2804, 2768, 1467, 1358 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$ 7.73 (d, *J* = 8.3, 2H), 7.34 (d, *J* = 8.3, 2H), 2.97-2.92 (m, 2H), 2.45 (s, 3H), 2.30-2.24 (m, 6H), 1.80-1.71 (m, 2H), 1.58-1.50 (m, 4H), 1.42-1.40 (m, 2H), 0.92 (s, 9H), 0.30 (s, 6H); <sup>13</sup>C NMR:  $\delta$  144.3, 129.8, 129.7 (2C), 129.1 (2C), 56.4, 54.4, 54.3 (2C), 25.9 (3C), 25.8 (2C), 24.34, 24.26, 21.5, 18.0, -4.4 (2C); MS *m*/*z* (%): 426 (M<sup>+</sup>, 4.68), 271 (100). Anal. Calcd for C<sub>21</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 59.11; H, 8.98; N, 6.57. Found: C, 59.28; H, 8.79; N, 6.51.



#### *N*-[3-(Pyrrolidin-1-yl)propyl]-*N*-(*tert*-butyldimethylsilyloxy)-4-methyl-benzen

**esulfonamide** (**12i**): It is a colorless oil (93%); IR: *v* 2957, 2931, 2858, 2791, 1466, 1357 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ7.73 (d, *J* = 7.9, 2H), 7.33 (d, *J* = 7.9, 2H), 3.00-2.96 (m, 2H), 2.44-2.39 (m, 9H), 1.83-1.74 (m, 6H), 0.92 (s, 9H), 0.30 (s, 6H); <sup>13</sup>C NMR: δ 144.4, 129.9, 129.8 (2C), 129.2 (2C), 54.4, 54.1 (2C), 53.8, 26.6, 25.9 (3C), 23.3 (2C), 21.6, 18.1, -4.3 (2C); MS *m*/*z* (%): 412 (M<sup>+</sup>, 0.22), 84 (100). Anal. Calcd for C<sub>20</sub>H<sub>36</sub>N<sub>2</sub>O<sub>3</sub>SSi: C, 58.21; H, 8.79; N, 6.79. Found: C, 58.39; H, 8.67; N, 6.91.



*N*-(**3**-Morpholinopropyl)-*N*-(*tert*-butyldimethylsilyloxy)-**4**-methyl-benzenesulf onamide (12j): It is a colorless oil (98%); IR: *v* 2943, 1358, 1169 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$ 7.73 (d, *J* = 7.9, 2H), 7.34 (d, *J* = 7.9, 2H), 3.69-3.66 (m, 4H), 3.00-2.95 (m, 2H), 2.45 (s, 3H), 2.40-2.31 (m, 6H), 1.78-1.73 (m, 2H), 0.92 (s, 9H), 0.30 (s, 6H); <sup>13</sup>C NMR:  $\delta$  144.4, 129.8, 129.7 (2C), 129.1 (2C), 66.8 (2C), 55.9, 54.1, 53.4 (2C), 25.9 (3C), 24.0, 21.5, 18.0, -4.4 (2C); MS *m*/*z* (%): 428 (M<sup>+</sup>, 0.53), 100 (100); Anal. Calcd for C<sub>20</sub>H<sub>36</sub>N<sub>2</sub>O<sub>4</sub>SSi: C, 56.04; H, 8.46; N, 6.54. Found: C, 56.21; H, 8.30; N, 6.63.



*N*-[**3**-(**4**-Methylpiperazin-1-yl)propyl]-*N*-(*tert*-butyldimethylsilyloxy)-**4**-methyl -benzenesulfonamide (**12k**): It is a colorless oil (93%), IR: *v* 2934, 1462, 1358 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  7.73 (d, *J* = 8.3, 2H), 7.34 (d, *J* = 8.3, 2H), 2.99-2.93 (m, 2H), 2.45-2.28 (m, 16H), 1.76-1.71 (m, 2H), 0.92 (s, 9H), 0.29 (s, 6H); <sup>13</sup>C NMR:  $\delta$  144.3, 129.8, 129.7 (2C), 129.1 (2C), 55.5, 54.9 (2C), 54.1, 52.9 (2C), 45.9, 25.9 (3C), 24.2, 21.5, 18.0, -4.4 (2C); MS *m*/*z* (%): 442 (M<sup>+</sup> + H, 100). Anal. Calcd for C<sub>21</sub>H<sub>39</sub>N<sub>3</sub>O<sub>3</sub>SSi: C, 57.10; H, 8.90; N, 9.51. Found: C, 57.29; H, 8.73; N, 9.48.



Preparation of (R)-2-Vinyl-1-piperidinepropanal Oxime (13a), A Typical Procedure of Oximation: A stirred mixture of compound 12a (453 mg, 1.0 mmol) and CsF (301 mg, 2 mmol) in MeCN (10 mL) was heated at 60 °C under N<sub>2</sub> for 2 h. After it was cooled to room temperature, saturated aqueous NH4Cl was added to quench the reaction. The resultant mixture was extracted by EtOAc (3 x 30 mL) and combined organic layers were washed with brine (20 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent gave a residue, which was purified by chromatography (silica gel, 30% EtOAc in PE) to give 171 mg (94%, E:Z = 72:28) of product **13a** as a white crystal. It had mp 43-45 °C (PE/EtOAc),  $[\alpha]_D^{20} = +11.2$  (c 0.2, CHCl<sub>3</sub>). IR: v 3305, 3179, 3073, 2931, 2854, 2789, 2726 cm<sup>-1</sup>; <sup>1</sup>H NMR (as a mixture of *E*:*Z* isomers):  $\delta$  11.06 (s, br, 1H), 7.37-7.32 (m, 0.28H, minor), 6.70-6.67 (m, 0.72H, major), 5.88-5.74 (m, 1H), 5.18-5.04 (m, 2H), 3.02-2.87 (m, 2H), 2.75-2.63 (m, 1H), 2.62-2.33 (m, 3H), 2.17-2.08 (m, 1H), 1.74-1.45 (m, 5H), 1.37-1.25 (m, 1H);  $^{13}$ C NMR:  $\delta$  149.8, 149.1, 140.7, 115.9, 66.2, 66.0, 51.9, 51.7, 51.5, 51.2, 32.8, 25.8, 25.2, 23.5, 21.4; MS *m/z* (%): 182 (M<sup>+</sup>, 0.42), 124 (100). Anal. Calcd for C<sub>10</sub>H<sub>18</sub>N<sub>2</sub>O: C, 65.90; H, 9.95; N, 15.37; Found: C, 65.95; H,

9.92; N,15.26.

By similar procedure, 4-methyl-benzenesulfonamides **12b-12k** were converted into **13b-13k**.



**3**-(*N*-Allyl-*N*-butylamino)propanal oxime (13b): It is a colorless oil (93%, dr = 72:28); IR: *v* 3207, 3077, 2957 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$ 10.40 (s, br, 1H), 7.42-7.38 (m, 0.28H, minor), 6.78-6.74 (m, 0.72H, major), 5.94-5.80 (m, 1H), 5.21-5.12 (m, 2H), 3.15-3.13 (m, 2H), 2.70-2.63 (m, 2H), 2.56-2.32 (m, 4H), 1.46-1.41 (m, 2H), 1.35-1.23 (m, 2H), 0.90 (t, *J* = 7.2, 3H), <sup>13</sup>C NMR:  $\delta$ 150.2, 149.7, 135.2, 117.7, 56.9, 56.8, 53.1, 53.0, 50.2, 49.4, 28.6, 28.5, 26.9, 22.5, 20.6, 14.0; MS *m*/*z* (%): 184 (M<sup>+</sup>, 0.22), 84 (100). Anal. Calcd for C<sub>10</sub>H<sub>20</sub>N<sub>2</sub>O: C, 65.18; H, 10.94; N, 15.20; Found: C, 65.35; H, 11.07; N, 15.04.



**3-**(*N*,*N*-**Diallylamino**)**propanal oxime** (**13c**): It is colorless oil (99%, dr = 66:34); IR: *v* 3200, 3076, 2977, 997 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ 9.00 (br, 0.66H), 8.25 (br, 0.34H), 7.44-7.40 (m, 0.34H, minor), 6.81-6.78 (m, 0.66H, major), 5.92-5.78 (m, 2H), 5.22-5.14 (m, 4H), 3.13 (d, *J* = 5.9, 4H); 2.68-2.62 (m, 2H), 2.56-2.50 (m, 1H), 2.40-2.33 (m, 1H); <sup>13</sup>C NMR: δ149.9; 149.4; 134.7, 134.6, 118.1, 118.0, 56.4, 56.2, 49.7, 48.9, 26.8, 22.3. MS *m*/*z* (%): 168 (M<sup>+</sup>, 0.15), 110 (100). Anal. Calcd for C<sub>9</sub>H<sub>16</sub>N<sub>2</sub>O: C, 64.25; H, 9.59; N, 16.65. Found: C, 64.07; H, 9.75; N, 16.46.



**3**-(*N*-Allyl-*N*-but-3-enyl)aminopropanal oxime (13d): It is a yellowish oil (97%, dr = 60:40); IR: *v* 3212, 3075, 2923, 2818 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  10.18 (s, br, 0.6H), 9.74 (s, br, 0.4H), 7.43-7.39 (m, 0.4H, minor), 6.79-6.76 (m, 0.6H, major), 5.94-5.69 (m, 2H), 5.22-4.95 (m, 4H), 3.17-3.14 (m, 2H), 2.72-2.65 (m, 2H), 2.59-2.51 (m, 3H), 2.40-2.34 (m, 1H), 2.27-2.22 (m, 2H); <sup>13</sup>C NMR:  $\delta$  150.3, 149.9, 136.4, 135.0, 134.9, 117.8, 115.7, 56.8, 56.7, 52.7, 52.6, 50.2, 49.4, 31.1, 31.0, 27.0, 22.6; MS *m*/*z* (%): 182 (M<sup>+</sup>, 0.05), 123 (100). Anal. Calcd for C<sub>10</sub>H<sub>18</sub>N<sub>2</sub>O: C, 65.90; H, 9.95; N, 15.37. Found: C, 66.03; H, 9.91; N, 15.54.



**3-(but-3-enyl(butyl)amino)propanal oxime (13e):** It is a yellowish oil (93%, dr = 67:33); IR: *v* 3216, 3076, 2956, 1080 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ10.06 (br, 1H), 7.44-7.40 (m, 0.33H, minor), 6.80-6.76 (m, 0.67H, major), 5.85-5.70 (m, 1H), 5.08-4.96 (m, 2H), 2.68-2.64 (m, 2H), 2.57-2.33 (m, 6H), 2.27-2.21 (m, 2H), 1.50-1.41 (m, 2H), 1.36-1.24 (m, 2H). 0.90 (t, *J* = 7.2, 3H); <sup>13</sup>C NMR: δ 150.4, 150.0, 136.5, 115.6, 55.33, 55.27, 53.1, 53.0, 50.6, 49.9, 31.1, 31.0, 28.7, 28.6, 27.1, 22.8, 20.6, 14.0; MS *m/z* (%): 198

(M<sup>+</sup>, 0.28), 139 (100). Anal. Calcd for C<sub>11</sub>H<sub>22</sub>N<sub>2</sub>O: C, 66.62; H, 11.18; N, 14.13. Found: C, 66.79; H, 11.03; N, 14.02.



**3**-(*N*-Benzyl-*N*-but-3-enyl)aminopropanal oxime (13f): It is a yellowish oil (98%, dr = 70:30); IR: *v* 3221, 3068, 2940, 1453, 1368 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ10.31 (br, 1H), 7.40-7.18 (m, 5.30H), 6.75-6.72 (m, 0.70H, major), 5.80-5.67 (m, 1H), 5.04-4.94 (m, 2H), 3.58 (s, 2H), 2.62-2.20 (m, 8H); <sup>13</sup>C NMR: δ150.6, 150.2, 138.7, 138.6, 136.5, 128.8 (2C), 128.0 (2C), 126.8, 115.5, 58.0, 57.9, 52.6, 52.5, 50.2, 49.3, 31.1, 31.0, 27.0, 22.6; MS *m*/*z* (%): 232 (M<sup>+</sup>, 0.72), 91 (100). Anal. Calcd for C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O: C, 72.38; H, 8.68; N, 12.06. Found: C, 72.23; H, 8.77; N, 12.20.



**3-(3,4-Dihydroisoquinolin-2(1H)-yl)propanal oxime (13g):** It is a white crystal (95%, dr = 64:36), mp 59-61 °C (PE/EtOAc); IR: *v* 3452, 3281, 2825, 935 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ9.91 (s, br, 1H), 7.45-7.40 (m, 0.36H, minor), 7.12-7.09 (m, 3H), 7.01-6.99 (m, 1H), 6.82-6.80 (m, 0.64H, major), 3.67 (s, 2H), 2.90-2.83 (m, 2H), 2.79-2.74 (m, 2H), 2.69-2.66 (m, 3H), 2.60-2.54 (m, 1H); <sup>13</sup>C NMR: δ150.1, 149.6, 134.1, 134.0, 128.5, 126.5, 126.1, 125.6, 55.4, 54.6, 54.0, 50.5, 50.4, 28.52, 28.47, 27.3, 23.0; MS *m*/*z* (%): 204 (M<sup>+</sup>, 0.36), 146 (100). Anal. Calcd for C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O: C, 70.56; H, 7.90; N, 13.71.

Found: C, 70.75; H, 7.94; N, 13.87.



**3-(Piperidin-1-yl)propanal oxime (13h):** It is a white crystal (94%, dr = 30:70), mp 85-87 °C (PE/EtOAc); IR: *v* 3411, 3248, 2945, 1123 cm<sup>-1</sup>; <sup>1</sup>H NMR: *δ*7.46-7.43 (m, 0.30H, minor), 6.86-6.85 (m, 0.70H, major), 2.58-2.39 (m, 8H), 1.65-1.57 (m, 4H), 1.49-1.34 (m, 2H); <sup>13</sup>C NMR: *δ*149.7, 149.1, 55.6, 55.1, 54.1, 54.0, 26.8, 25.3, 25.2, 24.0, 22.7; MS *m*/*z* (%): 156 (M<sup>+</sup>, 0.10), 98 (100). Anal. Calcd for C<sub>8</sub>H<sub>16</sub>N<sub>2</sub>O: C, 61.50; H, 10.32; N, 17.93. Found: C, 61.33; H, 10.39; N, 17.80.



**3-(Pyrrolidin-1-yl)propanal oxime (13i):** It is a yellow oil (70%, dr = 62:38); IR: *v* 3181, 2962, 2808, 1455, 910 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  9.98 (s, br, 1H), 7.44-7.40 (m, 0.38H, minor), 6.80-6.76 (m, 0.62H, major), 2.69-2.40 (m, 8H), 1.85-1.76 (m, 4H); <sup>13</sup>C NMR:  $\delta$  149.4, 148.9, 53.8, 53.7, 53.0, 52.4, 29.0, 24.6, 23.2; MS *m*/*z* (%): 142 (M<sup>+</sup>, 0.41), 84 (100). Anal. Calcd for C<sub>7</sub>H<sub>14</sub>N<sub>2</sub>O: C, 59.12; H, 9.92; N, 19.70. Found: C, 59.33; H, 9.83; N, 19.89.



**3-Morpholinopropanal oxime (13j):** It is a yellowish oil (89%, dr = 57:43); IR: *ν* 3185, 3077, 2957, 2862, 1454, 1306 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ9.64 (s, br, 0.43H), 9.23 (s, br, 0.57H), 7.46-7.42 (m, 0.43H, minor), 6.80-6.77 (m, 0.57H, major), 3.75-3.72 (m, 4H), 2.63-2.37 (m, 8H); <sup>13</sup>C NMR: δ150.1, 149.7, 66.7, 66.6, 55.5, 54.9, 53.32, 53.25, 26.8, 22.4; MS *m*/*z* (%): 158 (M<sup>+</sup>, 0.26), 100 (100). Anal. Calcd for C<sub>7</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>: C, 53.15; H, 8.92; N, 17.71. Found: C, 53.02; H, 8.90; N, 17.53.



**3-(4-Methylpiperazin-1-yl)propanal oxime (13k):** It is a colorless oil (65%, dr = 53:47); IR: *v* 3213, 2936, 1458, 1152 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ8.55 (s, br, 1H), 7.42-7.39 (m, 0.47H, minor), 6.76-6.72 (m, 0.53H, major), 2.69-2.55 (m, 10H), 2.47-2.35 (m, 5H); <sup>13</sup>C NMR: δ149.4, 148.8, 54.7, 54.2, 54.1, 51.52, 51.45, 45.0, 27.0, 22.6; MS *m/z* (%): 171 (M<sup>+</sup>, 5.57), 113 (100). Anal. Calcd for C<sub>8</sub>H<sub>17</sub>N<sub>3</sub>O: C, 56.11; H, 10.01; N, 24.54. Found: C, 56.32; H, 10.06; N, 24.63.



Preaparation of (10a*R*,9b*R*)-octahydro-1H-isoxazolo[4,3-a]quinolizine (14a), A typical procedure of INOC: To a stirred solution of compound 13a (91 mg, 0.5 mmol)

in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added an aqueous solution of NaOCl (10%, 0.9 mL) at 0 °C within 30 min. Then the reaction was stirred at room temperature for 2 h (monitored by TLC). After the reaction was quenched by H<sub>2</sub>O (20 mL), the resultant mixture was extracted by CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic layers were washed with brine (20 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent gave a residue, which was purified by chromatography (silica gel, 50% EtOAc in PE) to give 79 mg (88%) of product **14a** as a yellowish oil,  $[\alpha]_D^{20} = -30.4$  (c 0.9, CHCl<sub>3</sub>). IR: *v* 2929, 2856, 2800, 2763 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  4.50-4.43 (m, 1H), 3.83-3.77 (m, 1H), 3.08-2.93 (m, 3H), 2.76-2.70 (m, 1H), 2.55-2.45 (m, 1H), 2.20-2.03 (m, 2H), 1.80-1.54 (m, 5H), 1.38-1.16 (m, 2H); <sup>13</sup>C NMR:  $\delta$  157.7, 70.5, 67.3, 55.2, 55.1, 54.0, 32.3, 25.2, 24.7, 23.4. MS *m/z* (%): 180 (M<sup>+</sup>, 42.12), 179 (100). Anal. Calcd for C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O: C, 66.63; H, 8.95; N, 15.54. Found: C, 66.81; H, 8.89; N, 15.42.

By similar procedure, 3-aminopropanal oximes **13b-13d** were converted into **14b-14d**.



**5-Butyl-3,3a,4,5,6,7-hexahydroisoxazolo[4,3-c]pyridine** (**14b**): It is a yellow oil (90%); IR: *v* 2956, 2928, 1134 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ4.49-4.43 (m, 1H), 3.80-3.74 (m, 1H), 3.46-3.40 (m, 1H), 3.30-3.23 (m, 1H), 3.17-3.12 (m, 1H), 2.73-2.68 (m, 1H), 2.50-2.38 (m, 3H), 2.13-1.95 (m, 2H), 1.53-1.43 (m, 2H), 1.40-1.25 (m, 2H), 0.93 (t, *J* = 7.2, 3H); <sup>13</sup>C NMR: δ158.3, 70.7, 58.4, 57.0, 52.8, 47.7, 29.1, 24.9, 20.4, 13.8; MS *m/z* (%):

182 (M<sup>+</sup>, 25), 139 (100). Anal. Calcd for C<sub>10</sub>H<sub>18</sub>N<sub>2</sub>O: C, 65.90; H, 9.95; N, 15.37.
Found: C, 66.04; H, 10.02; N, 15.43.



**5-Allyl-3,3a,4,5,6,7-hexahydroisoxazolo[4,3-c]pyridine** (**14c**): It is a yellowish oil (86%); IR: *v* 3076, 2955, 2911, 1464, 1348 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ 5.92-5.78 (m, 1H), 5.24-5.18 (m, 2H), 4.51-4.44 (m, 1H), 3.82-3.75 (m, 1H), 3.50-3.03 (m, 5H), 2.74-2.71 (m, 1H), 2.51-2.39 (m, 1H), 2.13-1.98 (m, 2H); <sup>13</sup>C NMR: δ 157.9, 134.3, 118.1, 70.6, 60.2, 57.8, 52.4, 47.5, 24.7; MS *m*/*z* (%): 166 (M<sup>+</sup>, 43), 41 (100). Anal. Calcd for C<sub>9</sub>H<sub>14</sub>N<sub>2</sub>O: C, 65.03; H, 8.49; N, 16.85. Found: C, 65.20; H, 8.58; N, 16.81.



**5-(But-3-enyl)-3,3a,4,5,6,7-hexahydroisoxazolo[4,3-c]pyridine** (14d): It is a yellow oil (85%). IR: *v* 2926, 2804, 1361, 913, 845 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  5.88-5.73 (m, 1H), 5.13-5.00 (m, 2H), 4.52-4.44 (m, 1H), 3.82-3.75 (m, 1H), 3.46-3.37 (m, 1H), 3.31-3.25 (m, 1H), 3.19-3.13 (m, 1H), 2.75-2.69 (m, 1H), 2.58-2.39 (m, 3H), 2.31-2.24 (m, 2H), 2.18-2.03 (m, 2H); <sup>13</sup>C NMR:  $\delta$  158.2, 136.0, 115.8, 70.7, 58.2, 56.6, 52.6, 47.7, 31.4, 24.9; MS *m*/*z* (%): 180 (M<sup>+</sup>, 0.93), 139 (100). Anal. Calcd for C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O: C, 66.63; H, 8.95; N, 15.54. Found: C, 66.68; H, 8.81; N, 15.66.



(15,9aR)-Octahydro-1-hydroxymethyl-2H-quinolizin-2-one (15): At room temperature, a suspension of compound 14a (400 mg, 2.22 mmol), Raney nickel (13 mg, 0.22 mmol) and HOAc (1.33 g, 22.2 mmol) in aqueous MeOH (75%, 20 mL) under H<sub>2</sub> (balloon) was vigorously stirred for 1.5 h. Then the reaction was quenched by saturated aqueous Na<sub>2</sub>CO<sub>3</sub> (20 mL) and the catalyst was filtrated off. The filtration was extracted with EtOAc (3 x 20 mL) and combined organic layers were washed with brine (20 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent gave a residue, which was purified by chromatography (silica gel, EtOAc) to give 342 mg (84%) of product **15** as a white solid. It had mp 69-71 °C (EtOAc),  $[\alpha]_D^{20} = +8.8$  (c 0.04, CHCl<sub>3</sub>). IR: v 3440, 1714, 1092, 647 cm<sup>-1</sup>; <sup>1</sup>H NMR: δ3.97-3.93 (m, 1H), 3.74-3.68 (m, 1H), 3.14-3.05 (m, 1H), 3.00-2.96 (m, 1H), 2.83-2.70 (m, 2H), 2.46-2.33 (m, 3H), 2.17-2.07 (m, 2H), 1.98-1.95 (m, 1H), 1.83-1.56 (m, 3H), 1.40-1.20 (m, 2H); <sup>13</sup>C NMR: δ211.9, 63.0, 58.3, 56.6, 55.69, 55.67, 41.7, 31.1, 25.3, 23.3; MS *m*/*z* (%): 183 (M<sup>+</sup>, 28.76), 28 (100). Anal. Calcd for C<sub>10</sub>H<sub>17</sub>NO<sub>2</sub>: C, 65.54; H, 9.35; N, 7.64. Found: C, 65.81; H, 9.42; N, 7.56.



# (1S,9aR)-Octahydro-1-hydroxymethyl-spiro[1,3-dithiolane-2,2'-[2H]quinolizin e] (16): To a solution of compound 15 (293 mg, 1.60 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> was added a

mixture of ethane-1,2-dithiol (1.23 mL, 14.7 mmol) in BF<sub>3</sub>·Et<sub>2</sub>O (0.46 mL, 3.68 mmol). Two hours later, the reaction was quenched by aqueous NaOH (2.0 M, 3 mL). The resultant mixture was extracted by CH<sub>2</sub>Cl<sub>2</sub> (3 x 20 mL) and combined organic layers were washed with H<sub>2</sub>O (20 mL) and brine (20 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent gave a residue, which was purified by chromatography (silica gel, EtOAc) to give 344 mg (83%) of product **16** as a white solid. It had mp 128-130 °C (EtOAc),  $[\alpha]_D^{20} = -13.0$  (c 0.1, CHCl<sub>3</sub>). IR: *v* 3452, 1641, 1048, 1025 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  4.21-4.17 (m, 1H), 3.90-3.86 (m, 1H), 3.39-3.23 (m, 4H), 2.94-2.77 (m, 3H), 2.47-2.24 (m, 2H), 2.16-1.95 (m, 4H), 1.82-1.73 (m, 2H), 1.65-1.52 (m, 2H), 1.38-1.14 (m, 2H); <sup>13</sup>C NMR:  $\delta$ 711.8, 63.7, 61.3, 56.3, 55.2, 52.7, 44.9, 39.3, 38.7, 29.9, 25.3, 24.2; MS *m*/*z* (%): 259 (M<sup>+</sup>, 28.33), 97 (100). Anal. Calcd for C<sub>12</sub>H<sub>21</sub>NOS<sub>2</sub>: C, 55.56; H, 8.16; N, 5.40. Found: C, 55.51; H, 8.17; N, 5.44.



**Preparation of** (+)-**Epilupinine (2):** A suspension of compound **16** (260 mg, 1.00 mmol), Raney nickel (secondary grad, 900 mg, 15.3 mmol) in anhydrous EtOH (20 mL) was refluxed for 1.5 h. After the reaction was cooled to room temperature, the catalyst was filtrated off. Removal of the solvent gave a residue, which was purified by chromatography (silica gel, 25% MeOH in EtOAc) to give 161 mg (95%) of product **2** as a white solid. It had mp 77-79 °C (lit.<sup>[7b,7g]</sup> 78-79 °C),  $[\alpha]_D^{20} = +31.8$  (c 0.60, EtOH) [lit.<sup>[7b]</sup>  $[\alpha]_D^{20} = +32.6$  (c 0.72, EtOH), lit.<sup>[7g]</sup>  $[\alpha]_D^{22} = +31.2$  (c 0.86, EtOH)]. IR: *v* 3183,

2929, 2860, 1064 cm<sup>-1</sup>; <sup>1</sup>H NMR:  $\delta$  3.62-3.56 (m, 1H), 3.50-3.45 (m, 1H), 2.77-2.69 (m, 2H), 2.33 (s, br, 1H), 2.00-1.50 (m, 9H), 1.38-1.28 (m, 1H), 1.26-1.11 (m, 4H); <sup>13</sup>C NMR:  $\delta$  64.4, 64.3, 56.8, 56.6, 43.9, 29.7, 28.2, 25.5, 24.9, 24.5; MS *m*/*z* (%): 169 (M<sup>+</sup>, 42.96), 83 (100). Anal. Calcd for C<sub>10</sub>H<sub>19</sub>NO: C, 70.96; H, 11.31; N, 8.28. Found: C, 70.91; H, 11.34; N, 8.23.



S22





X : parts per Million : 1H



	der fasteringen og der fasteringen	101481444444444444444444444444444444444	ejezőségőnessegeszerentek			nutranakasan	eabierumachtes prisidentes (fild	tuya mana maini		na na sing na s	Mecahinism debuweeuu		Manie (1551-15-10) (16-10) (16-10)	nian with state		. The second	liter many many many many many many many many	i de formation of the data data data da	and and particular		Ming Panhang ya Anti (panjama) panja	aleeftikkeejdikkeergi
220.0	210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0	110.0	100.0	90.0	80.0 70.	0 60	).0	50.0	40.0	30.0	20.0	10.0	0
								140.9511		11 × 0074	±/00.011			77.4207 77.0000 76.5698	66,8944 64,1601	54,8958	51.7217		33,4895	25.5160 25.5160 23.3266		



X : parts per Million : 1H



X : parts per Million : 13C



X : parts per Million : 1H



X : parts per Million : 13C



X : parts per Million : 1H



X : parts per Million : 13C







X : parts per Million : 1H



X : parts per Million : 13C










![](_page_39_Figure_1.jpeg)

![](_page_40_Figure_0.jpeg)

![](_page_41_Figure_0.jpeg)

![](_page_42_Figure_0.jpeg)

![](_page_43_Figure_0.jpeg)

![](_page_44_Figure_0.jpeg)

![](_page_44_Figure_1.jpeg)

![](_page_45_Figure_0.jpeg)

![](_page_46_Figure_0.jpeg)

![](_page_47_Figure_0.jpeg)

nielzen speitsteren et als	an a	sauninunginensejikanjogramistykk	ويواله بولي المحصر والمحصر والمحصور والمح	tin taga ang mang ang	ૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡૡ	ناه، در میکونه این این این میکونه این	manage Harrison	nayaw hayarayaa	محرم معرومه محرمه معرومه مع معرومه معرومه مع معرومه معرومه معرومه معرومه معرومه معرومه معرومه مع معرومه مع معرومه معرومه معرومه معرومه معرومه معوومه معوومه معومه معوومه معوومه موموم مع مع معوومه مع معوومه م		\$2000.000 <u>20</u> 00.000 (00.000) (00.000)	*********************************	ana mangang kang mangan di Kanang kanang kang kang kang kang kang ka	ren i franski se	and and an and a second second	war Thereene	angan yang kang kang kang kang kang kang kang k	and hereas	and the former and the second s	ana na ana ang ang ang ang ang ang ang a	anguna ana mining ng pangapang pangapang pangapang pangapang pangapang pangapang pangapang pangapang pangapang
220.0	210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0 110.0	100.0	90.0	80.0	70.0	60.0	50.0	40.0	30.0	20.0	10.0	0
							149.7756 149.1446	140.7408		115.8927			77.4302 77.0000 76.5793	66.2156 65.9861		51.8651 51.5113 51.1576		32.8490	25.7837 25.2196 23.5369 21.3762		

					_		-		
								1 I.	
								1	
	[ ]								
	[ ]			li l					
	6 /								
	1								
						1 1		1 11	
$[a_{1},a_{2}] = a_{1},a_{2},a_{3},a_{4},a_{5},a_{4},a_{5},$	hoursenand	And a second and a second and a second secon	and and a second and a second s			Management and the second seco	annesses and a second	/harmon har har	โลก ให้เรืองสาวเราของสาวการสาวการสาวเรืองสาวเรืองสาวเราของสาวเราจะจะเหตุ

![](_page_48_Figure_2.jpeg)

![](_page_48_Figure_3.jpeg)

![](_page_49_Figure_0.jpeg)

![](_page_50_Figure_0.jpeg)

![](_page_51_Figure_0.jpeg)

![](_page_52_Figure_0.jpeg)

![](_page_53_Figure_0.jpeg)

13d	OH N La Idla 1488 1398 1368 1376 1358 1358 1358 E Idla 1488 1398 1388 1375 1358 1358 1358 E Idla 1488 1398 1388 1375 1358 1358 1358	sudy-99338-2-C-single police dev-2.jdf single pairs decoupled gated NOE	sudy-99030-2-C-single palse dec-2, jeff single palse decoupled gater NOE
lansektengenteesse paksenkeste dekse katolise fast partikeit on de meter konneksensen kulturen de steret de kes		a yes and the anythy second and part the second part of the se	
220.0 210.0 200.0 190.0 180.0 170.0	160.0 150.0 140.0 130.0 1 160.0 150.0 140.0 130.0 1 9668 051 1132 0528 1132 0528 1132 0528 1132 0528 1132 0528 1132 0528 1130 0588 1130 05888 1130 05888	20.0 110.0 100.0 90.0 80.0 70.0 5000 500 500 500 500 500 500 500 500 50	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

![](_page_55_Figure_0.jpeg)

yaa aaddadd	and an and the participation of	nanuni Mutut A	ىرىغىدىيە يەرىپەرىيە يەرىپەر يەرىپەرىيە يەرىپەرىيە يەرىپەر يەرىپەر يەرىپەر يەرىپەر يەرىپەر يەرىپەر يەرىپەر يەر يەرىپەر يەرىپەر	ndi samekina kasin kara	an a	1.9.030000000000000000000000000000000000	ويليل ومرد ومرديه والمراسية	Net discut della contra transformation	גער לאראליער איז אין איז אין איז איז אין איז	ulah Kalon Woor K. «Wow	en de la constante de la const La constante de la constante de	ann ann an ann ann ann ann ann ann ann	ndariationetskonsela, neve nevera	والمحماد بمواديهم المعاوديان	ndernderst Lee witnensen Mit, staaten	dhe minhedrodikad	ed 1962. Else de ser de Martine
220.0	210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0 130	.0 120.0 110.0	100.0	90.0	80.0 70.0	60.0 50.0	40.0	30.0 20.0	10.0	0
							150.3875 (49.9763	136.5436	115.5772			77.4302 77.0000 76.5793	53.3374 53.2705 52.9741 49.8573		31.0803 30.9942 28.7379 28.6423 27.0552 22.7912 20.6018	13.9763	

and and the and the second and the second of the second and the second

OH N 13e

![](_page_57_Figure_0.jpeg)

![](_page_58_Figure_0.jpeg)

![](_page_59_Figure_0.jpeg)

![](_page_60_Figure_0.jpeg)

-- ----

![](_page_61_Figure_0.jpeg)

![](_page_62_Figure_0.jpeg)

![](_page_62_Figure_1.jpeg)

![](_page_63_Figure_0.jpeg)

![](_page_64_Figure_0.jpeg)

![](_page_65_Figure_0.jpeg)

220.0	210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0	110.0	100.0	90.0	80.0	70.0	60.0	50.0	40.0	30.0	20.0	10.0	0
							150.1389 149.7469							77.4207 77.0000 76.5793	66.6745 66.6171	55.4503	54.8767 53.3279 53.2514		26.7875	22.4374		

![](_page_66_Figure_1.jpeg)

![](_page_66_Figure_2.jpeg)

0\_\_\_\_\_

13j

![](_page_66_Figure_3.jpeg)

![](_page_67_Figure_0.jpeg)

![](_page_68_Figure_0.jpeg)

![](_page_69_Figure_0.jpeg)

![](_page_70_Figure_0.jpeg)

![](_page_71_Figure_0.jpeg)




X : parts per Million : 13C





220.0	210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0	110.0	100.0	90.0	80.0	70.0	60.0	50.0		40.0	30.0	20.0	10.0	0
						157.8925			8//77-PCT	118.1107				77.4302 77.0000 76.5793	70.6039	60.2211 57.8309	52.4483	47.5437		24.7129	Ì		



220.0	210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0	110.0	100.0	90.0	80.0	70.0	60.0	50.0	40.0	30.0	20.0	10.0	0
						158.2080		135.9987		115 7071	TIZICIT			77.4302 77.0000 76.5793	70.7282	58.2325 56.5880	52.6299	4/.00/1	31.3766	24.9041		

			L.					
 กรูปไปไปได้กระบบการที่สารที่สุข <sup>1</sup> ระบบสีมีกระบบการเป็นเป็นเป็นเป็นเป็นเป็นเป็น	masalinetastang tanggi tanggi ang tanggi ang tanggi tanggi tanggi tanggi tanggi tanggi tanggi tanggi tanggi tan	<sup>a</sup> layol <sub>a</sub> langi kabulang migangkingkanakang kabulang kabulang migangkingkanakanakan	warman was	super-representation	handham	n provide a second s	www.www.www.	landerahltungen operationstranisischels teleperationsen





X : parts per Million : 1H







sudywatywaty	tay wasan wasa da fa	ing stylesting for some some some	elelog secondo se posono	4444754724969567249695678397	nor-tonartijAlingonaact	stfrawlernelsenflik	setundetion/sequences	anderhalder, van der	halponumenterrist	singengenerthessensjoch.	engel frånghelde som forste som fo	Neyinga Magalan Salah	enter and a second a	portional and <sup>11</sup> preserve theorem	weeks to receive	freed 19 why barr	angeledrosed false	the part in the second	spuritions before	al Victorinopance	el y booling har booling was a	ligen og finner som figteret
220.0	210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0	110.0	100.0	90.0	80.0 70.0	60.	.0 50	.0	40.0	30.0	20.0	10.0	0
														207 000 703 703	534 919	239 495 682	667	642 714	043	343 062		



